352 related articles for article (PubMed ID: 28755165)
1. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
3. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
[TBL] [Abstract][Full Text] [Related]
4. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
5. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
[TBL] [Abstract][Full Text] [Related]
7. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
8. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
9. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
Manousaridis K; Peter-Reichart S; Mennel S
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
[TBL] [Abstract][Full Text] [Related]
11. The Portuguese Experience with Ocriplasmin in Clinical Practice.
Figueira J; Martins D; Pessoa B; Ferreira N; Meireles A; Sampaio A; Carneiro Â; Vaz F; Nascimento J; Moreno N; Roque J; Domingues M; Flores R; Teixeira C; Conde E; Henriques F; Proença H; Pita Negrão J; Barbosa M; Silva R; Vaz-Pereira S; Pereira Neves P; Gomes N; Raimundo M;
Ophthalmic Res; 2016; 56(4):186-192. PubMed ID: 27438077
[TBL] [Abstract][Full Text] [Related]
12. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
[TBL] [Abstract][Full Text] [Related]
13. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
14. Ocriplasmin versus vitrectomy for the treatment of macular holes.
Juncal VR; Chow DR; Vilà N; Kapusta MA; Williams RG; Kherani A; Berger AR
Can J Ophthalmol; 2018 Oct; 53(5):441-446. PubMed ID: 30340707
[TBL] [Abstract][Full Text] [Related]
15. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
[TBL] [Abstract][Full Text] [Related]
16. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
17. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
[TBL] [Abstract][Full Text] [Related]
18. [Microstructural retinal changes after pharmacological vitreolysis with ocriplasmin-an SD-OCT supported analysis].
Groselli S; Wehrmann K; Rüther K; Feucht N; Lohmann CP; Maier M
Ophthalmologe; 2020 Mar; 117(3):260-266. PubMed ID: 31346704
[TBL] [Abstract][Full Text] [Related]
19. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance.
Muqit MMK; Hamilton R; Ho J; Tucker S; Buck H
PLoS One; 2018; 13(5):e0197072. PubMed ID: 29768451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
